{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:20:48Z","timestamp":1781601648678,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The etiology of Guillain\u2013Barr\u00e9 syndrome (GBS) may be autoimmune. About two-thirds of patients typically experience their first symptoms within 5 days to 3 weeks after common infectious diseases, surgery, or vaccination. Infection is a triggering factor for over 50% of patients. In recent years, a growing number of studies have indicated that some immune checkpoint inhibitors and COVID-19 may also contribute to the occurrence of GBS. However, drugs are considered a rare cause of GBS. The patient in our case was a 70-year-old man who developed GBS after initiating secukinumab for psoriasis. Upon diagnosis suggesting a potential association between secukinumab and the development of GBS, as per the Naranjo adverse drug reaction (ADR) probability scale, we decided to discontinue the drug. Following this intervention, along with the administration of immunoglobulin, the patient exhibited a significant improvement in extremity weakness. The association of GBS with secukinumab treatment, as observed in this case, appears to be uncommon. The underlying mechanisms that may link secukinumab to the development of GBS are not yet fully understood and warrant further scientific inquiry and rigorous investigation. However, we hope that this report can raise greater awareness and vigilance among medical professionals to enhance the safety of patients\u2019 medication.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1412470","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T04:41:21Z","timestamp":1719549681000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case report and brief literature review: possible association of secukinumab with Guillain\u2013Barr\u00e9 syndrome in psoriasis"],"prefix":"10.3389","volume":"15","author":[{"given":"Gang","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ci","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001163","article-title":"Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/jcm12041662","article-title":"Interleukin-17 vs. Interleukin-23 inhibitors in pustular and erythrodermic psoriasis: A retrospective, multicentre cohort study","volume":"12","author":"Avallone","year":"2023","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001510","article-title":"Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study","volume":"134","author":"Zhao","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.21814","article-title":"Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy","volume":"54","author":"Shin","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200210000-00015","article-title":"Recent advances in drug-induced neuropathies","volume":"15","author":"Peltier","year":"2002","journal-title":"Curr Opin Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1136\/bmj.328.7455.1537","article-title":"Guillain-Barre syndrome seen in users of isotretinoin","volume":"328","author":"Pritchard","year":"2004","journal-title":"BMJ"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-induced demyelinating polyradiculoneuropathy","volume":"375","author":"de Maleissye","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26101","article-title":"Guillain-Barre-like syndrome during pembrolizumab treatment","author":"Ong","year":"2018","journal-title":"Muscle Nerve"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook","volume":"8","author":"Mohn","year":"2019","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323124","article-title":"Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies","volume":"91","author":"Fargeot","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2191-7","article-title":"A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use","volume":"142","author":"Jacob","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27024","article-title":"COVID-19-associated Guillain-Barre syndrome: The early pandemic experience","volume":"62","author":"Caress","year":"2020","journal-title":"Muscle Nerve"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02001-z","article-title":"Long-term neurologic outcomes of COVID-19","volume":"28","author":"Xu","year":"2022","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab186","article-title":"A case of multifocal motor neuropathy after initiation of ixekizumab for psoriatic arthopathy","volume":"60","author":"McKenna","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac609","article-title":"Guillain-Barre syndrome is associated with ixekizumab in a patient with pustular psoriasis","volume":"62","author":"Liu","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"P2.451","DOI":"10.1212\/wnl.90.15_supplement.p2.451","article-title":"Ustekinumab related CIDP in a patient with psoriatic arthritis (P2.451)","volume":"90","author":"Gamaleldin","year":"2018","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2013.05.005","article-title":"Th1\/Th2\/Th17\/Treg cytokines in Guillain-Barre syndrome and experimental autoimmune neuritis","volume":"24","author":"Zhang","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5836-5","article-title":"The role of cytokines in Guillain-Barre syndrome","volume":"258","author":"Lu","year":"2011","journal-title":"J Neurol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e15740","DOI":"10.1111\/dth.15740","article-title":"Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: A case report","volume":"35","author":"Gelato","year":"2022","journal-title":"Dermatol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3573-1","article-title":"Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barr\u00e9 syndrome after anti-TNF-\u03b1 treatment? Case report and literature review","volume":"36","author":"Psarelis","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.immuni.2020.06.022","article-title":"The cytokine IL-17A limits th17 pathogenicity via a negative feedback loop driven by autocrine induction of IL-24","volume":"53","author":"Chong","year":"2020","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.immuni.2023.06.012","article-title":"An autonomous activation of interleukin-17 receptor signaling sustains inflammation and promotes disease progression","volume":"56","author":"Luo","year":"2023","journal-title":"Immunity"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1412470\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T04:41:23Z","timestamp":1719549683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1412470\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2024.1412470"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1412470","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]},"article-number":"1412470"}}